1st Edition
Ischemic Injury A Molecular Insight
The World Stroke Organization reports that "Stroke has already reached epidemic proportions. Globally 1 in 4 adults over the age of 25 will have a stroke in their lifetime. 12.2 million people worldwide will have their first stroke this year and 6.5 million will die as a result. Over 110 million people in the world have experienced stroke." Ischemic strokes are the most common type of stroke, with about 87% of all strokes being ischemic strokes.
This new volume helps to address this epidemic by presenting detailed studies on ischemic injury, with emphasis on the molecular-level mechanisms and the role of signaling pathways in the body, their structure, and their mechanism of action. The book focuses on molecular pharmacology plans and explains the new areas of research on the discovery of new therapeutic molecules that can be used for combating this life-threatening disease.
The significant etiologies of ischemic and hemorrhagic stroke are reviewed in detail. The authors discuss stroke occurrence at different stages of life, such as sex-based differences in the treatment of ischemic injury. The COVID-19 pandemic has created an elevated incidence and risk of ischemic stroke, which is addressed in the volume. The authors cover aspects of the clinical treatment and diagnosis of patients with cardiovascular events, including in-depth information on the prevention, evaluation, therapy selection, result projection, and long-term course of the disease in affected patients. The authors describe the effect of stroke in daily life as well as complications for prevention of stroke. They also detail the involvement of platelets, neurotransmitters, renin-angiotensin-aldosterone system, and vitamin-D in ischemic injury. This book outlines the various aspects of recognizable proof of preclinical and clinical improvement
This book also looks at the pharmacological aspects that incorporate physiology of a disease, receptor-connected intracellular weak structure, different transduction pathways, and multiple I/R injuries.
Medical researchers, medical students, and medical and neurology residents who handle patients with acute stroke syndromes will find this volume to be a valuable resource. The book will be important to experts on the cutting-edge of molecular pharmacology, detailing the most recent improvements in cell and receptors pharmacology with a noteworthy emphasis on the system of activity of novel medications being worked on for ischemic injury.
1. Stroke Insight
Heena Khan, Thakur Gurjeet Singh, and Rahul Deshmukh
2. Myocardial Ischemic-Reperfusion Injury
Heena Khan, Thakur Gurjeet Singh, and Rahul Deshmukh
3. Preclinical and Clinical Aspects of I-R Injuries
Shilpa Kumari, Rahul Deshmukh, and Thakur Gurjeet Singh
4. Molecular Aspects of Ischemic-Reperfusion Injury
Maanvi, Shilpa Kumari, Chaman Sharma, Rahul Deshmukh, and Thakur Gurjeet Singh
5. Role of Mitochondria in Ischemic-Reperfusion Injury
Narinder Kumar, Kajal Bagri, Shahid Mushtaq Malik, Rahul Deshmukh, and Thakur Gurjeet Singh
6. Stroke Effect in Daily Life and Therapeutics, Complications for Prevention of Stroke
Kumari Tanuja, Kajal Bagri, Rajni Thakur, Rahul Deshmukh, and Thakur Gurjeet Singh
7. Etiopathogenesis and Molecular Targets in Cerebral Ischemia: Current Understanding of Stroke and Therapeutic Approaches
Manish Kumar, Shivani Bagga, and Thakur Gurjeet Singh
8. Expatiating the Pivotal Role of Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Ischemic Stroke: Molecular Insights and Therapeutic Targets
Shiveena Bhatia, Varinder Singh, Manjinder Singh, Ravinder Singh, Richa Shri, and Thakur Gurjeet Singh
9. Acute Ischemic Stroke in COVID-19 Patients
Piyush Vatsha, Kajal Bagri, Sakshi Rana, Rahul Deshmukh, and Thakur Gurjeet Singh
10. Neurotransmission Imbalance: A Major Factor in the Worsening of Ischemic Injury
Kajal Bagri, Vipasha Mehta, Aarchi Singla, Rahul Deshmukh, and Thakur Gurjeet Singh
11. Role of the Renin-Angiotensin-Aldosterone System (RAAS) in Amelioration of Stroke Pathophysiology
Rajender Sandhu, Shilpa Kumari, Smriti Thakur, Rahul Deshmukh, and Thakur Gurjeet Singh
12. Stroke and Diabetes in Vitamin D Deficiency: Prospects of Intertwined Pathobiologies
Ravinder Singh, Sanjana Mehta, Vertika Awasthi, Pratima Kumari, Varinder Singh, and Thakur Gurjeet Singh
13. Remote Ischemic Post-Conditioning: An Overview
Heena Khan, Shivani Bagga, Manish Kumar, Thakur Gurjeet Singh, and Rahul Deshmukh
14. Sex-Based Differences in Acute Kidney Injury: Lessons from Renal Ischemia-Reperfusion Injury Model in Rodents
Tajpreet Kaur and Amrit Pal Singh
15. Critical Overview of Conditioning Techniques and Their Current Status in the Treatment of Myocardial Ischemia-Reperfusion Injury
Kuldeep Kumar, Nirmal Singh, and Amteshwar S. Jaggi
16. Involvement of Platelets in Myocardial Ischemia and Reperfusion Injury
Geeta Deswal, Benu Chaudhary, Preeti Arya, Deepak Singla, and Ajmer Singh Grewal
17. Recent Advancements in Strategies for Treatment of Cerebral Ischemia
Uditi Handa, Kajal Nagpal, Peeyush Kaushik, and Ajmer Singh Grewal
18. Recent Therapeutic Approaches Toward the Management of Ischemic Heart Disease
Deepika Purohit, Nirmala Kumari Yadav, Jyoti Rathi, Sunil Kumar, and Snehlata Yadav
19. Nanotechnology-Assisted Treatment for Ischemic Heart Disease and Recent Patents
Manish, Sunil Kumar, Manu Sharma, Nirmala Kumari Yadav, and Deeksha
20. Major Risk Factors Involved in the Pathobiology of Ischemic Brain and Heart Disorders
Priyanka Sharma, Suray Ranjan, Kajal Bagri, Rahul Deshmukh, and Thakur Gurjeet Singh
21. Modulating Mitogen-Activated Protein Kinase (MAPK) Downstream Signaling Pathways in Cerebral Ischemic Hemorrhages
Gurpreet Singh, Shamsher Singh, and Sidharth Mehan
22. Implication of Mitogen-Activated Protein Kinase (MAPK) in Cerebral Stroke
Shamly, Shilpa Kumari, Paras Attri, Rahul Deshmukh, and Thakur Gurjeet Singh
23. Regulation of JNK Signaling Pathway in Ischemia-Reperfusion Injury
Veerta Sharma, Heena Khan, Amarjot Kaur Grewal, Thakur Gurjeet Singh, and Rahul Deshmukh
24. Role of Glycogen Synthase Kinase-3? (Gsk-3?) in Intracranial Haemorrhage
Khadga Raj, Sudhanshu Mallan, Ayansh Kaushik, and Shamsher Singh
25. Role of GSK-3 Inhibition in Modulating the Pathology of Stroke
Rupali Sharma, Shilpa Kumari, Satyan Kapoor, Rahul Deshmukh, and Thakur Gurjeet Singh
26. Regulation of NRF-2 Signaling Pathway in Ischemia-Reperfusion Injury
Veerta Sharma, Heena Khan, Amarjot Kaur Grewal, Thakur Gurjeet Singh, and Rahul Deshmukh
27. Regulation of PI3K-AKT Signaling Pathway in Ischemia-Reperfusion Injury
Komal Thapa, Heena Khan, Amarjot Kaur Grewal, Thakur Gurjeet Singh, and Rahul Deshmukh
28. COVID-19 and Ischemic Stroke: Advancements and Challenges
Rupinder Kaur Sodhi, Renu Arya, Vinay Kumar, Jitender Madan, and Arockia Babu
Biography
Thakur Gurjeet Singh, PhD, MPharm, has 16 years of experience in industry, research, and teaching. He is working as Dean, Chitkara College of Pharmacy, Chitkara University, Punjab, India. He is engaged with projects on interception of nicotine, morphine, alcohol dependence, ischemia, diabetic neuropathy and nephropathy toxicology, epilepsy, Alzheimer’s disease, and stem cell research studies and handles affiliation formalities with the director’s office. He has also attended UGC networking courses and various preclinical and clinical research training programs. He has more than 182 research publications (international and national) and 25 book chapters, eight books and 58 patents filed under his name. To date, he has 170 Scopus-indexed publications in peer-reviewed journals (with 1778 citations, an h-index 22 and i10-index 58, impact factor: 482.5 and RG score: 37). He has attended more than 60 national and international conferences. He has guided theses for 65 MPharm students and is supervising 10 PhD candidates. He is a reviewer for various highly reputed international journals. He is a member secretary of the Committee for the Purpose of Control and Supervision of Experiments on Animals and is the In-Charge of the animal house facility at Chitkara College of Pharmacy. He is also a member secretary for institutional human ethical committee registered with the Department of Health Research and CDSCO New Delhi, India.
Heena Khan, PhD, MPharm, has over five years of experience in research. She is working as a Junior Research Fellow. She is engaged with several projects on stroke, diabetes, Alzheimer’s disease, and Parkinson’s disease. She has more than 30 research and review publications (international), which have been cited in highly reputed journals. She is a reviewer for various highly reputed international journals. She has participated and attended several national and international conferences. She is also a member of the International Society for Pharmacoeconomics and Outcomes Research.
